
Celldex Therapeutics upgraded to Buy after positive Phase 3 trial results for skin drug barzolvolimab.
Celldex Therapeutics received a Buy rating upgrade from H.C. Wainwright, with the price target raised to $64 from $42, following successful Phase 3 clinical trials of barzolvolimab. The drug showed rapid and lasting benefits for patients with a chron...





